Gastroesophageal Reflux Disease
Pipeline by Development Stage
Drug Modality Breakdown
Gastroenterology is a $7.3B market characterized by mature, blockbuster-driven portfolios with near-term patent cliff risks.
Key Trends
- AbbVie dominance with 43% of top-10 product spending (LINZESS, CREON, RINVOQ)
- Guanylate cyclase activators and JAK inhibitors driving innovation in constipation and IBD
- Multiple patent expirations 2026–2030 creating biosimilar and generic erosion headwinds
Career Verdict
Gastroenterology offers stable, well-compensated roles but limited growth upside; best for risk-averse professionals seeking established markets over innovation-driven career trajectories.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LINZESS (linaclotide) | AbbVie | $1.8B | 25% | Peak | Stable | 7.7yr |
| 2 | CREON (pancrelipase) | AbbVie | $1.5B | 21% | LOE Approaching | Declining | |
| 3 | XIFAXAN (rifaximin) | Bausch Health | $1.1B | 15% | LOE Approaching | Declining | |
| 4 | RINVOQ (upadacitinib) | AbbVie | $976M | 13% | Peak | Growing | 11.8yr |
| 5 | XELJANZ XR (tofacitinib) | Pfizer | $586M | 8% | Peak | Stable | 8.3yr |
Drug Class Breakdown
mature portfolio anchor
well-established class
facing biosimilar competition
growing IBD adoption
commoditized
Career Outlook
StableGastroenterology is a stable, mature market anchored by blockbusters with long patent runways (LINZESS to 2034, RINVOQ to 2038) but faces near-term erosion (XELJANZ 2026). Employment growth is modest and concentrated in device/diagnostic firms rather than pure-pharma. Best for professionals seeking predictable revenue streams over high-risk innovation bets.
Breaking In
Target roles at Roche, J&J, or diagnostic-adjacent firms to maximize hiring volume; pure pharma gastro entry points at AbbVie/Pfizer are limited and highly competitive.
For Experienced Professionals
Leverage gastro expertise in broader GI/immunology roles (Takeda, Novartis) or transition to medical devices/diagnostics where hiring is 3x higher than pharma.
In-Demand Skills
Best For
Hiring Landscape
Total hiring across the gastro ecosystem is 1,818 jobs, dominated by engineering (434) and commercial roles (269). Roche leads absolute hiring at 377 roles, followed by Johnson & Johnson (323) and GE HealthCare (293), reflecting broad medical device and diagnostic involvement alongside pharma. AbbVie's gastro-specific hiring (78 jobs) is modest relative to its portfolio dominance.
By Department
Manufacturing and commercial roles command premium salaries ($213K and $176K respectively), but total gastro-pharma hiring is concentrated in Roche and J&J, not pure-play GI companies.
On Market (2)
Approved therapies currently available
Competitive Landscape
20 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 16,107 patients across 50 trials
PREA, PK And Safety PASS Study Of IV Pantoprazole In Pediatric Subjects
An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan
Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease
Phase IV Study of the Impact of Dietary Fibers on Symptoms and Esophageal Motility in Patients With Non-erosive GERD
To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy
Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US
A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI)
Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD
Symptom Adapted Therapy in GERD Patients
Esomeprazole in PPI Failures - IMPROVE
Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD
Treatment of Zollinger-Ellison Syndrome With Prevacid
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv
Safety and Efficacy of Lansoprazole in Patients With Reflux Disease
A Double-blind Comparative Study of the Efficacy and Safety of E3810 10mg Once and Twice Daily in Maintenance Therapy for PPI Resistant Gastroesophageal Reflux Disease Patients
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy
A Safety and Efficacy Study of Lansoprazole in Preventing Aspirin-Induced Gastric and Duodenal Ulcers
Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease
Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn
Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis
A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old
A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients
A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD)
Safety and Efficacy of Dexlansoprazole Delayed-Release Capsules in Treating Symptomatic Non-Erosive Gastroesophageal Reflux Disease in Adolescents
Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)
An Explorative Trial to Evaluate the Pharmacodynamic Effect of SPD557 on Reflux Parameters in Refractory GERD Patients
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis
A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.
Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole
Maintenance Intermittent Therapy for Symptomatic GERD Patients
Intravenous vs Oral Lansoprazole on Gastric Acid Secretion in Subjects With Erosive Esophagitis
A Study to Evaluate Vonoprazan in Children Who Have Symptomatic Gastroesophageal Reflux Disease
A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules
A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants
Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants
PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects
Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects
A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics of TAK-117 (MLN1117) in Healthy Participants
Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets
Related Jobs in Gastroenterology
Senior Scientist, Computational Chemistry
Firmware Engineer - Medical Device
Senior Product Manager, Chat AI & Automation
Software Engineer I/II, Machine Learning
Sr Account Manager - China
People Partner (maternity cover 12 months)
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.